News from grünenthal group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

10 Sep, 2019, 16:24 BST Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in allogeneic cellular medicines for...


02 May, 2019, 14:11 BST Five Young Scientists Win EFIC-Grünenthal Grant 2018

The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as...


22 Jan, 2019, 10:28 GMT Grünenthal: Fabian Raschke Appointed Chief Financial Officer (CFO)

Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will...


14 Dec, 2018, 07:00 GMT Grünenthal and OnDosis Team Up for Individualised Dosing of Oral Drugs in Pain Management to Increase Patient Safety

Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis' technology for prescription...


03 Dec, 2018, 10:27 GMT Grünenthal Closes Deal With AstraZeneca for Nexium and Vimovo

Grünenthal today announced the successful completion of its acquisition of European rights to Nexium and global (ex US and Japan) rights to Vimovo...


14 Nov, 2018, 08:27 GMT Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to...


05 Nov, 2018, 12:04 GMT Grünenthal Acquires Global Rights for Qutenza®

Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for ...


30 Oct, 2018, 08:34 GMT Grünenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium and Vimovo

Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management...


28 Aug, 2018, 13:46 BST Duzallo®, a Fixed-dose Combination Therapy for Gout, Approved in Europe

Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use...


21 Jun, 2018, 10:00 BST Grünenthal, Lead Discovery Center and Max Planck Society Enter Into a Research Collaboration on Charcot-Marie-Tooth 1A (CMT1A)

Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a...


18 Jun, 2018, 12:18 BST EFIC: Fresh Ideas in Pain Research

Creative approaches to research by young scientists provide opportunity for new and challenging thinking to benefit patients who suffer from pain. To ...


15 Jun, 2018, 13:39 BST Grünenthal Selected as One of the Best Employers in Europe for the Third Time

Grünenthal has qualified as one of the 25 Best Multinational Workplaces in Europe this year. After 2012 and 2013, this is the third time that...


12 Jun, 2018, 12:25 BST Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate...


09 Apr, 2018, 08:30 BST Grünenthal and KU Leuven Join Forces to Develop an Innovative Non-Opioid Pain Treatment

Grünenthal, the Katholieke Universiteit Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR)...


01 Feb, 2018, 11:11 GMT Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP)...


23 Jan, 2018, 10:58 GMT Grünenthal to Distribute, Promote, and Sell MSD's Women's Health Products in Several Countries in Latin America

Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for...


19 Jan, 2018, 11:03 GMT Grünenthal Group Receives CE-Certification for Innovative Surgical Sealant

Grünenthal announced today that Adhesys Medical GmbH, a wholly-owned subsidiary of the Grünenthal Group, has received CE-Certification for MAR-CUTIS...


15 Jan, 2018, 05:00 GMT Grünenthal and Mundipharma Enter Commercial Partnership in China

Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market ...


05 Dec, 2017, 07:06 GMT New Partnership for the Commercialization of Nucynta® in the U.S. Territory

The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc.,...


16 Nov, 2017, 10:41 GMT Research Consortium led by Grünenthal Receives € 2 Million Grant from the European Fund for Regional Development and the State of North Rhine-Westphalia

- "LifeSciences.NRW" grant to support the discovery and development of new pain relief drugs - Grünenthal founded and leads the Consortium to which...


07 Sep, 2017, 17:00 BST Aging Demographics Require Novel Ideas in Pain Research

Significant unmet medical needs in the field of pain in Europe have made pain research more relevant than ever. On the occasion of the congress of...


01 Sep, 2017, 05:00 BST Mark Fladrich Takes Office as the New CCO of the Grünenthal Group

Responsibility for the entire Global Commercial Organization Strengthen the interface between Commercial and Research and Development (R&D) to...


07 Jul, 2017, 14:42 BST Grünenthal Group: Launch of the Project - Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)

The new research project NGN-PET was launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership...


14 Jun, 2017, 11:55 BST Grünenthal's CEO Demands Intensive Cooperation With All Stakeholders to Improve Health Care

Gabriel Baertschi addresses the improvement of pain policies in speech at Societal Impact of Pain symposium During his speech at the Societal Impact...


07 Jun, 2017, 09:00 BST Grünenthal Enters Agreement with AstraZeneca to Acquire Global Rights to Migraine Treatment Zomig® (Zolmitriptan)

This acquisition further strengthens Grünenthal's leading position in pain indications With migraine, Grünenthal adds another major pain indication...